EXAS vs GANX · rev $2.76B vs $53.0M cap
EXACT Sciences Corporation (EXAS) versus Gain Therapeutics Inc (GANX) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Gain Therapeutics Inc (GANX) is a biotechnology company listed on US.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
GANX does not have a complete income-statement cache yet.
EXAS currently screens at market cap $20.03B. GANX currently screens at market cap $53.0M.
Not investment advice. Open the EXAS and GANX stock pages for the full models.
Not investment advice.